Nothing Special   »   [go: up one dir, main page]

ZA200709959B - Triazine compounds and compositions thereof for the treatment of cancers - Google Patents

Triazine compounds and compositions thereof for the treatment of cancers

Info

Publication number
ZA200709959B
ZA200709959B ZA200709959A ZA200709959A ZA200709959B ZA 200709959 B ZA200709959 B ZA 200709959B ZA 200709959 A ZA200709959 A ZA 200709959A ZA 200709959 A ZA200709959 A ZA 200709959A ZA 200709959 B ZA200709959 B ZA 200709959B
Authority
ZA
South Africa
Prior art keywords
cancers
compositions
treatment
triazine compounds
triazine
Prior art date
Application number
ZA200709959A
Other languages
English (en)
Inventor
Gagnon Lyne
Zacharie Boulos
Penney Christopher
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of ZA200709959B publication Critical patent/ZA200709959B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200709959A 2005-05-19 2006-05-19 Triazine compounds and compositions thereof for the treatment of cancers ZA200709959B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68237405P 2005-05-19 2005-05-19

Publications (1)

Publication Number Publication Date
ZA200709959B true ZA200709959B (en) 2009-04-29

Family

ID=37430913

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200709959A ZA200709959B (en) 2005-05-19 2006-05-19 Triazine compounds and compositions thereof for the treatment of cancers

Country Status (11)

Country Link
US (1) US20090075867A1 (fr)
EP (1) EP1881835A4 (fr)
JP (1) JP2008540585A (fr)
CN (1) CN101180061A (fr)
AU (1) AU2006246958A1 (fr)
BR (1) BRPI0610351A2 (fr)
CA (1) CA2608463C (fr)
MX (1) MX2007014435A (fr)
NZ (1) NZ563245A (fr)
WO (1) WO2006122431A1 (fr)
ZA (1) ZA200709959B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138338B2 (en) 2006-07-31 2012-03-20 Glaxosmithkline Llc Aurora kinase inhibitors from an encoded small molecule library
US8119798B2 (en) 2006-08-01 2012-02-21 Glaxosmithkline Llc P38 kinase inhibitors
MX2009011850A (es) * 2007-04-30 2010-02-11 Prometic Biosciences Inc Derivados de triazina, composiciones que contienen dichos derivados, y metodos para el tratamiento de cancer y enfermedades autoinmunes utilizando dichos derivados.
WO2009069668A1 (fr) * 2007-11-28 2009-06-04 National University Corporation Nagoya University Agent pour augmenter l'expression d'un antigène du mélanome malin, et son utilisation
EA201992765A1 (ru) 2017-05-24 2020-03-25 Новартис Аг Белки на основе антител с привитым цитокином и способы их применения в лечении рака
CN112316151B (zh) * 2020-10-30 2023-01-13 天津大学 一种基于共价三嗪环骨架化合物的纳米载体及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189014A (en) 1979-12-03 1993-02-23 Cowan Jr Fred M Method of treating cellular Fc receptor mediated hypersensitivity immune disorders
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
US6645964B1 (en) * 1999-11-29 2003-11-11 Aventis Pharma S.A. Chemical derivatives and their application as antitelomerase agent
ATE322265T1 (de) * 2000-05-15 2006-04-15 Celgene Corp Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
CO5380035A1 (es) * 2001-03-23 2004-03-31 Aventis Pharma Sa Derivados quimicos y su aplicacion como agente antitelomerasa
FR2822468B1 (fr) * 2001-03-23 2008-06-20 Aventis Pharma Sa Derives chimiques et leur application comme agent anti-telomerase
KR20100107509A (ko) * 2001-09-14 2010-10-05 9222-9129 퀘벡 인코포레이티드 히스톤 데아세틸라아제의 억제제
JP2006503864A (ja) * 2002-10-01 2006-02-02 ジヨンソン・アンド・ジヨンソン・フアーマシユーチカル・リサーチ・アンド・デベロツプメント・インコーポレーテツド タンパク質チロシンキナーゼ阻害剤としての４，６−ジアミノ置換−２−［オキシ又はアミノキシ］−［１，３，５］トリアジン
JP5160788B2 (ja) 2003-11-24 2013-03-13 プロメティック、バイオサイエンシーズ、インコーポレーテッド 化合物、その化合物を含む組成物、その化合物を利用した自己免疫疾患の治療方法
MX2007002728A (es) 2004-09-03 2008-03-04 Prometic Biosciences Inc Compuestos basados en 2,4,6-triamino-5-triazina que se unen a la porcion de cola de inmunoglobulinas y su uso.

Also Published As

Publication number Publication date
CA2608463A1 (fr) 2006-11-23
CA2608463C (fr) 2015-02-03
MX2007014435A (es) 2008-04-16
NZ563245A (en) 2011-04-29
EP1881835A4 (fr) 2010-04-07
AU2006246958A1 (en) 2006-11-23
CN101180061A (zh) 2008-05-14
BRPI0610351A2 (pt) 2010-06-15
US20090075867A1 (en) 2009-03-19
WO2006122431A1 (fr) 2006-11-23
JP2008540585A (ja) 2008-11-20
EP1881835A1 (fr) 2008-01-30

Similar Documents

Publication Publication Date Title
HK1127489A1 (en) Pyridiazinone derivatives for the treatment of tumours
PL1765391T3 (pl) Kompozycje bakteryjne do leczenia nowotworów
ZA200800907B (en) Treatment of cancer
IL186973A0 (en) Compositions and methods for treatment for neoplasms
IL187999A0 (en) Compositions for the treatment of persistent infections
ZA200904492B (en) Compositions and methods for the treatment of infections and tumors
IL188430A0 (en) Treatment of tumors
ZA200708575B (en) Methods and compositions for treating or preventing cancer
EP2049151A4 (fr) Méthodes et compositions pour le traitement du cancer
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
EP1855662A4 (fr) Methodes et compositions destinees a traiter le cancer
HK1117780A1 (en) Compounds and methods for the treatment of cancer
EP1838330A4 (fr) Traitement de cancers solides
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
EP1908459A4 (fr) Composition prévenant le cancer
ZA200710206B (en) Compositions and methods for inhibition of the JAK path-way
EP1867640A4 (fr) Agent pour le traitement d'une tumeur solide
ZA200709959B (en) Triazine compounds and compositions thereof for the treatment of cancers
EP1979487A4 (fr) Compositions de cobalamine pour le traitement du cancer
IL186021A0 (en) Oxaprozin or closely related compound for the treatment and prevention of pruritus
EP1904088A4 (fr) Compositions et methodes de traitement du cancer
IL186606A0 (en) Compositions and uses of amooranin compounds
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
EP1951282A4 (fr) Traitement de l'hypersensibilité
GB0517387D0 (en) Combinations for the treatment of cancer